ProCE Banner Activity

SWOG S1801: Neoadjuvant vs Adjuvant Treatment With Pembrolizumab in Patients With Resectable Stage III-IV Melanoma

Slideset Download
Conference Coverage
Neoadjuvant therapy with pembrolizumab significantly improved event-free survival compared with pembrolizumab as adjuvant therapy in patients with resectable stage III-IV melanoma.

Released: September 23, 2022

Expiration: September 22, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.